EOLS — Evolus, Inc.

Evolus, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Global Net Revenue: $73.1 million, a 7% increase year-over-year.
  • Jeuveau Revenue: $66.4 million, with unit growth and pricing stability.
  • Evolisse Revenue: $6.7 million.
• Adjusted EBITDA: Positive at $0.6 million, improving from a loss of $5.5 million in Q1 2025.
• Gross Margin: Reported at 67%, adjusted gross margin at 68%.
• Operating Expenses: GAAP operating expenses were $55.7 million; non-GAAP operating expenses were $49.1 million.
• Cash Position: $49.8 million in cash and equivalents, with access to an additional $120 million in capital.

2. Strategic Updates and Business Highlights

• Evolus reported strong momentum from Q4 2025, achieving its second consecutive quarter of positive adjusted EBITDA.
• The company maintained a 14% market share for Jeuveau and gained share with Evolisse, supported by a differentiated commercial model and a cash-pay platform.
• The Performance Beauty platform integrates customer engagement, product ordering, and consumer loyalty, enhancing operational efficiency.
• Evolus is focusing on expanding its product portfolio, with the upcoming launch of Esteem in Europe and expected FDA approval for Sculp in Q4 2026.
• The company has seen total purchasing accounts increase by nearly 500, with over 18,000 customers having purchased from Evolus.

3. Forward Guidance and Outlook

• Evolus expects full-year 2026 revenue of $327 million to $337 million, with adjusted gross margin of 65.5% to 67%.
• The company anticipates high single-digit growth for Jeuveau and total company revenue growth of 10% to 13%.
• Confidence in achieving full-year adjusted EBITDA profitability remains strong.

4. Bad News, Challenges, or Points of Concern

• Tariff Risk: A 15% tariff on certain pharmaceutical products from South Korea, effective September 2026, poses a potential challenge, although Evolus is exploring mitigation strategies.
• Market Dynamics: The filler market remains flat to slightly down, with ongoing competitive pressures and a need for Evolisse to gain traction against established brands.
• Seasonality: Q1 is typically the lowest revenue quarter, and there were one-time revenue deferral dynamics affecting comparisons to the prior year.

5. Notable Q&A Insights

• Evolisse Launch: While the filler market is experiencing headwinds, the sentiment among clinicians is improving, and Evolisse is gaining confidence and reorder rates as clinics gain experience with the product.
• Competitive Landscape: The entry of new competitors like Hugel has not significantly impacted Evolus's market share, which remains stable.
• Market Recovery: There are signs of recovery in the aesthetics market, particularly with the influx of GLP-1 patients seeking aesthetic treatments.
• Future Product Pipeline: Evolus is actively seeking biostimulator assets and other innovations to enhance its product offerings, with a focus on skin quality and hair treatments.

Overall, Evolus demonstrated strong financial performance in Q1 2026, with a positive outlook despite some market challenges and competitive pressures. The company is strategically positioned for growth with its innovative product pipeline and operational efficiencies.